Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A

Summary

In the present study, we have analyzed the T cell receptor (TCR) repertoires of CD4+ T cells isolated from peripheral blood of 10 inhibitor-positive patients with severe hemophilia A. The distribution of complementarity determining region (CDR3) lengths of the beta chain of the TCRs was analyzed by spectratyping prior to and following in vitrostimulation of the cells with human factor VIII (FVIII). The repertoires of CD4+ T cells of patients were perturbed when compared to those of healthy blood donors. The perturbations of T cell repertoires were heterogeneous among patients with respect to the number and the nature of V-beta (BV) families that exhibited expansion following incubation with FVIII. Some patients showed alterations in one or two BV families, others exhibited more perturbed repertoires affecting 5 to 8 of the 14 BV families tested. Alterations of BV2, BV5 and/or BV9 were consistently found after incubation of CD4+ T cells in the presence of FVIII in 80% of the patients. These findings indicate that the presence of FVIII inhibitors in patients with severe hemophilia A is associated with measurable perturbations of the CD4+ T cell repertoire that results from oligoclonal expansion of FVIII-specific cells and may be relevant for the design of strategies aimed at modulating the anti-FVIII immune responses by T cell-targeted therapy

Keywords

Hemophilia A - FVIII Inhibitor - T lymphocytes - T cell-receptors - Repertoire development

• References

• 1 Peake I. The molecular basis of haemophilia A. Haemophilia 1998; 4: 346
• 2 de Biasi R, Rocino A, Papa ML. et al Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
• 3 Schwaab R, Brackmann HH, Meyer C. et al Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
• 4 Lacroix-Desmazes S, Moreau A. Sooryanarayana et al. Catalytic activity of antifactor VIII antibodies (FVIII inhibitors) in patients with hemophilia A. Nature Med 1999; 5: 1044-7.
• 5 Lacroix-Desmazes S, Bayry J, Misra N. et al The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346: 662-7.
• 6 Singer ST, Addiego Jr. JE, Reason DC. et al T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
• 7 Reding MT, Wu H, Krampf M. et al CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
• 8 Jacquemin M, Vantomme V, Buhot C. et al CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
• 9 Qian J, Borovok M, Bi L. et al Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
• 10 Sasgary M, Ahmad RU, Schwarz HP. et al Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
• 11 Wu H, Reding M, Qian J. et al Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
• 12 Reding MT, Wu H, Krampf M. et al Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
• 13 Ria F, van den Elzen P, Madakamutil LT. et al Molecular characterization of the T cell repertoire using immunoscope analysis and its possible implementation in clinical practice. Curr Mol Med 2001; 1: 297-304.
• 14 Verbruggen B, Novakova I, Wessels H. et al The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
• 15 Benveniste O, Cherin P, Maisonobe T. et al Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001; 167: 3521-9.
• 16 Roglic M, Macphee RD, Duncan SR. et al Theofilopoulos A N. T cell receptor (TCR) BV gene repertoires and clonal expansions of CD4 cells in patients with HIV infections. Clin Exp Immunol 1997; 107: 21-30.
• 17 Gorochov G, Neumann AU, Kereveur A. et al Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998; 4: 215-21.
• 18 Beurton I, Bertrand MA, Bresson-Hadni S. et al Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients. Eur J Gastroenterol Hepatol 2001; 13: 859-64.
• 19 English KE, Brien WF, Howson-Jan K. et al Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy. Ann Pharmacother 2000; 34: 737-9.
• 20 Reding MT, Lei S, Lei H. et al Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-75.
• 21 Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
• 22 Claret EJ, Alyea EP, Orsini E. et al Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100: 855-66.
• 23 Yoshizawa K, Ota M, Katsuyama Y. et al T cell repertoire in the liver of patients with autoimmune hepatitis. Hum Immunol 1999; 60: 806-15.
• 24 Grabowska AM, Lechner F, Klenerman P. et al Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001; 31: 2388-94.
• 25 Umemura T, Yoshizawa K, Ota M. et al Analysis of T cell repertoire in the liver of patients with chronic hepatitis C. Clin Exp Immunol 2000; 121: 120-6.
• 26 Turner SJ, Diaz G, Cross R. et al Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity 2003; 18: 549-59.
• 27 Ouyang Q, Wagner WM, Walter S. et al An age-related increase in the number of CD8(+) T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev 2003; 124: 477-85.
• 28 Cibotti R, Cabaniols JP, Pannetier C. et al Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J Exp Med 1994; 180: 861-72.
• 29 Prisco A, Troncone R, Mazzarella G. et al Identical T-cell receptor beta chain rearrangements are present in T cells infiltrating the jejunal mucosa of untreated celiac patients. Hum Immunol 1997; 55: 22-33.
• 30 Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Haemost 2000; 26: 179-88.
• 31 Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
• 32 Ewenstein BM, Hoots WK, Lusher JM. et al Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85: 35-9.
• 33 Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci Res 1996; 43: 391-402.
• 34 Aissaoui A, Klingel-Schmitt I, Couderc J. et al Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol 1999; 46: 559-67.
• 35 Qian J, Burkly LC, Smith EP. et al Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
• 36 Rossi G, Sarkar J, Scandella D. Longterm induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
• 37 Patterson AE, Korngold R. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 187-96.